AstraZeneca Offloads Two Mature CV Drugs For $500m

China Medical System has agreed to pay a total of $500m for selected rights to two mature AstraZeneca cardiovascular products, with the divestments set to provide new growth prospects for the Chinese firm while helping the UK-based multinational focus on innovative products in its second-largest global market.